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Introduction
Multiple sclerosis (MS) shows highest incidence 
during young adult age.1,2 However, due to the 
chronic character of the disease, an increasing 
proportion of patients is now elderly.3 Focal 
inflammatory activity of the disease as reflected by 
relapse rates or magnetic resonance imaging 
(MRI) activity generally is reduced with age.4,5 On 
the other hand, elderly patients often have comor-
bidities such as arterial hypertension or diabetes 
mellitus, which may complicate MS treatment.6 
In addition, these patients may be affected by a 
phenomenon named immunosenescence, which 
comprises aging-associated changes in the innate 
and adaptive immune response, chronic antigenic 
stimulation and the occurrence of endogenous 
macromolecular changes, as well as the presence 
of senescent cells exhibiting a senescence-associ-
ated secretory phenotype.7
The effectiveness and safety of drug treatment may 
depend on patient age (e.g. owing to disease dura-
tion, immunosenescence and concomitant disease) 
and previous treatment.8 An age-associated loss 
of relative efficacy has been reported for some MS 
drugs, including natalizumab9 and fingolimod,10 
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whereas potentially severe adverse drug reactions 
have been reported to be overrepresented in older 
patients.11
Teriflunomide is a once-daily oral immunomodu-
lator approved in >80 countries for treating relaps-
ing MS (RMS), including clinically isolated 
syndrome, relapsing-remitting MS, and active sec-
ondary progressive MS, depending on the local 
label.12,13 Whereas patients with a relatively broad 
age range were investigated in the clinical trial pro-
gramme, the upper age limit was commonly 
restricted to 55 years. To overcome this restriction, 
we resorted to the non-interventional TAURUS-MS 
I study, a large contemporary cohort of real-world 
MS patients in Germany, where teriflunomide is 
used commonly for mild to moderate forms of 
relapsing-remitting MS; under European 
Medicines Agency approval, teriflunomide should 
be used with caution in patients aged 65 and above 
due to insufficient data on safety and efficacy.14
We specifically investigated whether age and pre-
treatment status have an effect on effectiveness 
and safety of teriflunomide under routine clinical 
practice conditions in unselected MS patients.
Methods
Details of the TAURUS-MS I study (‘Therapie 
mit Aubagio® unter Praxisbedingungen: 
Wirksamkeit, Lebensqualität und Verträglichkeit 
bei Patienten mit schubförmiger Multipler 
Sklerose’) have been reported previously.15 In 
short, this was a non-interventional, prospective, 
longitudinal study performed by 307 office-based 
and hospital-based neurologists across Germany 
from 2014 to 2017. The study was approved 
locally by the Ethic Committee at the Ruhr-
University of Bochum, Faculty of Medicine under 
number 4874-13, as well as registered in the 
BfArM public study database under number 2075.
Patients were eligible for documentation if they 
were aged ⩾18 years (with no upper age limit), had 
a diagnosis of relapsing-remitting MS, provided 
written patient informed consent, were capable of 
completing questionnaires, and had no contraindi-
cations to Aubagio® (teriflunomide, approved 
dose 14 mg once daily). Data were obtained at 
entry, after 3 months, and 6, 12, 18 and 24 months. 
Documented parameters included demographics, 
information on MS (date of onset and diagnosis, 
type, number of relapses, disability), previous 
disease modifying therapy (DMT) use, fatigue as 
measured using the fatigue severity scale (FSS), 
treatment satisfaction questionnaire of medication 
(TSQM) and adverse events (AEs).16
Statistical analysis
Analyses were done in an exploratory manner 
using descriptive statistical methods. For contin-
uous variables, the number of patients with non-
missing and missing data, mean, standard 
deviation, minimum, 25% quantile, median, 75% 
quantile and maximum were calculated. For ordi-
nal and categorical variables, frequencies were 
calculated. Incomplete data sets were included in 
the analysis. There was no imputation of missing 
values for any endpoint. No sensitivity analyses 
were done.
Subgroups were defined by (a) patient age (18–
25 years, 26–35, 36–45, 46–55, 56–65 and 66+ 
years), and (b) pre-treatment with MS drugs (no 
pre-treatment, pre-treatment stopped within 
6 months before start of teriflunomide). Subgroup 
analyses were performed independent from each 
other, and each patient is considered in both 
analyses.
The safety analysis set (patients with case report 
form available or AE report from study available) 
comprised 1139 patients; the effectiveness analy-
sis set (teriflunomide-treated patients who com-
plied with the protocol) comprised 1128 patients.
Clinical results were analysed by visit. For the 
analysis of relapse rate, the Wilcoxon matched-
pairs signed-ranks test was used, because the 
number of relapses showed a positively skewed 
distribution. Changes from baseline were ana-
lysed by repeated measurement analysis for time 
trends. Analyses were carried out with the statisti-
cal tool SPSS for Windows (version 15.0.0). As 
an exception, confidence intervals (CI) of cate-
gorical variables were calculated with the statisti-
cal software BIAS version 10.12.
Results
Data from 1128 patients who fulfilled the inclu-
sion criteria and fully complied with the protocol 
were analysed.
Information on patients at inclusion is provided 
in Table 1. Overall, mean age of patients was 
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44.9 ± 10.2 years, with mean time since MS diag-
nosis 8.9 ± 7.6 years. Mean Expanded Disability 
Status Scale (EDSS) was 2.3 ± 1.5 (0.0–7.0). 
While the mean number of MS relapses was 
0.6 ± 0.8 over the past 12-months prior to study 
entry, a substantial proportion of patients (52.7%) 
had no relapse during this interval.
Subgroups by age
A total of 558 (49.5%) patients were above 
45 years old, with 131 patients in the age group 
>55–65 and 19 patients being over 65 years old. 
The proportion of females rose with increasing 
age (from 39.5% in patients aged 18–25 years to 
73.7% in patients aged 66+ years; Table 1). As 
expected, compared with younger age groups (18–
25 and 26–35 years old), older patients had a 
longer disease duration, more comorbidities, and 
a higher grade of disability by EDSS; however, 
they had less active disease with a lower number of 
relapses. All MS induced symptoms (e.g. depres-
sion, fatigue, cognitive deficits) were reported 
more frequently in patients aged 46+ years. 
Fatigue was the most common complaint across 
all age groups (56.5%); however, fatigue clearly 
increased with age (⩽25 years 23.3%; >65 years 
68.4%). In terms of effectiveness, the relapse rate 
within 1 year under teriflunomide treatment was 
reduced significantly by more than half in any age 
group, including the higher age groups of patients 
above 45 years, compared with the year before 
teriflunomide initiation (Table 2; Figure 1). 
Compared with baseline, EDSS remained stable 
in all age groups during the 24-month observation 
period (Table 2). Also, FSS scores remained 
nearly unchanged from baseline to last visit; how-
ever, in patients aged 36–45 years it improved 
slightly (p ⩽ 0.05; Table 2).
Subgroups by pre-treatment
Out of the 1128 patients, one quarter (n = 280, 
24.8%) had not received prior MS treatment and 
593 patients (52.6%) had stopped prior treat-
ment in the period from 6 months to 1 day before 
teriflunomide initiation (‘switchers’, Table 2). Of 
the recently pre-treated patients, 253 had received 
interferon-β (IFN-β), and 119 glatiramer acetate 
(i.e. injection therapies). Reasons for treatment 
switches were not reported. Patients without and 
with pre-treatment were about the same age, but 
MS disease history (11.0 versus 7.3 years since 
first symptoms), EDSS score at baseline (2.4 
versus 1.8) and rate of MS-associated symptoms 
(e.g. fatigue 59.5% versus 43.9%) differed in 
recently pre-treated patients versus patients with 
no pre-treatment. Further, in pre-treated patients, 
the number of relapses was lower (past 12 months: 
0.48 versus 0.82 events).
Both treatment-naïve and pre-treated patients 
experienced a reduction of the relapse rate per 
year after 12 months of teriflunomide therapy 
compared with the year before teriflunomide ini-
tiation (treatment-naïve: 0.82 ± 0.73 at BL to 
0.25 ± 0.55; pre-treated 0.48 ± 0.76–0.22 ± 0.50; 
both p ⩽ 0.001).
The change in the EDSS score in the pre-treated 
(‘switcher’) group after 24 months compared with 
baseline was not significant (+0.08, p = 0.183), 
while the change in the treatment-naïve group 
was significant (+0.25; p ⩽ 0.05). The FSS score 
was stable in treatment-naïve patients, whereas it 
improved slightly (−0.19; p ⩽ 0.05) in pre-treated 
patients from baseline to last visit.
Patient satisfaction with treatment
In pre-treated patients all three domains of 
TSQM improved substantially after 24 months 
compared with baseline (p ⩽ 0.001; Table 2). The 
majority of pre-treated patients received either 
IFN-β or glatiramer acetate before initiation of 
teriflunomide and were therefore analysed sepa-
rately. In patients pre-treated with injectable ther-
apies, all three domains of TSQM improved 
substantially after 24 months compared with 
baseline global satisfaction +15.9 ± 25.4 points 
(n = 145; p ⩽ 0.001), effectiveness 
+7.1 ± 28.6 points (n = 145; p ⩽ 0.01), conveni-
ence + 17.3 ± 27.2 points (n = 144; p ⩽ 0.001; 
Figure 2). Effects on the convenience and global 
satisfaction TSQM scales were numerically 
smaller in patients aged 46 years and above com-
pared with the younger age groups (Table 2).
Safety
The number of patients with AEs was lowest in 
patients aged 26–35 years (29.2%), whereas there 
was no clear difference among the other age 
strata; this observation also held true for serious 
AEs [7.7% (26–35 years); 15.0% (46–55 years; 
Table 3)]. With focus on specific infectious AEs, 
viral upper respiratory tract infections and influ-
enza did not appear to increase with increasing 
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age (Table 3). The rate of patients with infections 
(irrespective of severity and type) was very similar 
in patients aged ⩽45 years and those aged 
>45 years.
A total of 97 patients (8.6%) discontinued teriflu-
nomide treatment due to AEs, and the rate of dis-
continuations was higher in patients >45 years 
(61 cases; 62.9%) compared with the younger age 
Figure 1. Relapse rate per year after 12 months treatment with teriflunomide versus 12 months before 
treatment, by age group. Columns display relapse rates per year at baseline, including the 12-month period 
prior teriflunomide treatment (blue), and after 12-month teriflunomide treatment (red). Whiskers are SD. 
Comparisons of relapse rates after 12 months versus baseline within each age group were made with two-
tailed t tests.
*p < 0.05, **p ⩽ 0.01, ***p ⩽ 0.001.
BL, baseline; SD, standard deviation.
Figure 2. Mean change from baseline in TSQM global satisfaction, effectiveness, and convenience scores to 
24 months among ‘switchers from injectables.’ Analysis based on pre-treated patients who received either 
IFN-β or glatiramer acetate (i.e. injection therapies) before switch to teriflunomide. Columns display mean 
changes compared with baseline; whiskers are SD. All changes were statistically significant in two-tailed t 
tests.
**p ⩽ 0.01. ***p ⩽ 0.001.
BL, baseline; IFN-β, interferon beta; SD, standard deviation; TSQM, treatment satisfaction questionnaire of medication.
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groups (36 cases; 37.1%; p ⩽ 0.01). The most 
common AEs leading to discontinuations overall 
were diarrhoea, alopecia and nausea. In patients 
aged 46 years and above, for example, hyperten-
sion (n = 4) and arthralgia (n = 3) were reasons for 
discontinuation that were not noted as reasons in 
younger patients (Supplemental Table S1).
Comparisons between age groups on blood labo-
ratory values were not feasible due to different 
standard values of site laboratories.
The number of patients with AEs or serious AEs 
was lower in the pre-treated compared with the 
treatment-naïve group (34.2% versus 40.0% and 
12.2% versus 15.4%, respectively). The pattern of 
events appeared to be similar across groups.
Discussion
The TAURUS-MS I study was one of the first to 
report experience with teriflunomide under 
practice conditions in a real-world MS popula-
tion.15 Of note, 49.5% of patients were aged 
45 years and above, and 24.8% of the observed 
patients had been treatment-naïve. In this analy-
sis from the TAURUS-MS I study we demon-
strate that patients of all age groups and 
irrespective of pre-treatment status exhibit a 
decrease of disease activity in terms of relapses 
under teriflunomide treatment. However, older 
patients may discontinue treatment more often 
due to side effects.
Age in randomised clinical trials in MS typically 
caps at 50–55 years. Data from elderly MS 
patients are limited and of special interest in 
view of the fact that an increasing proportion of 
patients, often after long-term management of 
their disease, are now in the higher age groups. 
In addition, the aging process is accompanied by 
remodelling of the immune system, which may 
lead to a decline in immune responses as reflected 
in increased vulnerability to infectious diseases, 
diminished responses to vaccination and a sus-
ceptibility to age-related inflammatory dis-
eases.17 Immunosenescence-associated changes 
may also add to the effects produced by immu-
nomodulatory and immunosuppressive medica-
tions in MS.8 Currently approved therapies for 
MS are effective in preventing relapse but might 
be less useful in preventing the accumulation of 
disability associated with aging and disease 
progression.18
The original clinical development plan of teriflu-
nomide comprised 29 clinical studies, of which 
12 were phase II and III studies.14 Across the 
whole population of studies, there were predomi-
nantly female patients (72.3%), with a median 
age of 39 years. So far, data on teriflunomide from 
clinical trials on the elderly is limited.19 The old-
est subject in the clinical development program 
(phase I–III) was aged 65 and none above this age 
was exposed to teriflunomide, leading to recom-
mendations for cautionary use in patients aged 
65 years and above.14
The current analysis indicates that teriflunomide 
is equally effective in patients of younger and 
older age groups: over time, EDSS was stable, 
and the reduction of relapse rates compared with 
the pre-treatment period was not age-dependent.
Fatigue is consistently reported as the most prev-
alent and persistent symptom in MS, with pro-
found effects on quality of life, work capabilities 
and activities of daily living.20 Data on fatigue 
prevalence are very limited in the elderly MS pop-
ulation. Interferon therapy in MS has been asso-
ciated with fatigue,21 and changing from interferon 
to glatiramer acetate has already been associated 
with improvement of fatigue and work/activity 
impairment and quality of life, respectively.22,23 
Indeed, the FSS score in pre-treated patients 
(many of them previous IFN users) in 
TAURUS-MS I improved under teriflunomide. 
Patient satisfaction, as measured with the TSQM, 
improved efficacy and convenience domains in 
pre-treated patients, the latter being in line with 
the general finding that oral medications are more 
convenient than injectables.24
The prescribing information states in the section 
‘switching to teriflunomide’ that there is no wait-
ing period required when teriflunomide is initi-
ated after INF-β or glatiramer acetate, but does 
not contain information about efficacy when pur-
suing this approach. The current analysis pro-
vides real-world data suggesting that, irrespective 
of pre-treatment, patients benefit from terifluno-
mide treatment.
In terms of the effect of pre-treatment MS medi-
cation, subgroup analyses of the teriflunomide 
TEMSO study are of interest.25 In this rand-
omized, double-blind, placebo-controlled, paral-
lel-group trial, out of 1086 MS patients with 
relapses, 27.1% had been pre-treated with 
BA Kallmann, S Ries et al.
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previous MS medication in the last 2 years before 
inclusion. Pre-treated patients had a lower rela-
tive risk for MS relapse compared with treatment-
naïve patients (each versus placebo, 14 mg dose): 
0.60 (95% CI 0.43–0.85) versus 0.70 (95% CI 
0.45–0.92).25 Given the number of treatment 
options and the possibility of medication switches 
in routine clinical treatment of MS patients, it is 
important to note from our study that pre-treat-
ment does not interfere with effectiveness or 
safety of later treatment with teriflunomide.
In total, AEs occurred in 35.7% of patients, with 
97 patients (8.6%) discontinuing treatment due 
to AEs. The higher discontinuation rate in the 
elderly as shown in TAURUS-MS I is a typical 
finding.18,26 Against this background, safety 
results must be interpreted with caution. 
Teriflunomide treatment appeared not to be 
associated with increased infections in elderly 
patients compared with younger patients under 
real world conditions. Especially for viral respira-
tory tract infections and influenza there was no 
clear difference across the age groups.
Further methodological considerations must be 
taken into consideration when discussing the pre-
sent results. As limitations, the TAURUS-MS I 
study used an observational design, which may lead 
to unquantifiable selection bias of MS patients (e.g. 
underrepresentation of critically ill individuals).27 
MS patients in the study may be more compliant 
than non-participating persons.28 The loss-to-fol-
low-up rate over time was substantial, as in other 
observational MS studies.29 Of note, the magnitude 
of the relapse rate reduction compared with baseline 
should be considered with caution. Patients who 
were treatment naïve likely were starting treatment 
after a new diagnosis of MS accompanied by 
relapses in the past year. Similarly, patients who 
switched off IFN-β or glatiramer acetate may have 
had breakthrough disease activity. Therefore, 
regression to the mean likely contributed to the 
decrease in relapses,30 in particular as this variable 
has substantial within-subject variability over time.31
Strengths of the study comprise the large number 
of patients, and focus on the ambulatory setting 
rather than on university or specialist centres, bet-
ter reflecting real world situations.
In conclusion, in this large real-life cohort, 
patients of all age groups including older patients 
(who typically are excluded from older trials of 
DMTs), and irrespective of pre-treatment, bene-
fit from teriflunomide treatment in routine clini-
cal practice.
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